Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
depression
Biotech
Definium’s LSD depression drug produces ‘best ever’ ph. 3 data
The biotech’s LSD recipe, DT120 ODT, scored wins on all primary and key secondary endpoints of the 149-patient Emerge trial.
Darren Incorvaia
Jun 22, 2026 7:00am
Neumora's navacaprant strikes out in phase 3 depression studies
Jun 15, 2026 10:16am
GLP-1s may combat depression through a mood-boosting gut microbe
Jun 10, 2026 11:00am
Autobahn races toward ph. 3 after midstage bipolar depression win
Jun 4, 2026 11:31am
Seaport, Hemab prepare IPOs to fund depression, clotting drugs
Apr 13, 2026 7:12am
FDA approves 1st nondrug, at-home treatment for depression
Dec 11, 2025 6:00am
